Regeneron Pharma Earnings, Revenue Beat in Q1
2022.05.04 13:56
Regeneron Pharma Earnings, Revenue Beat in Q1
Investing.com – Regeneron Pharma (NASDAQ:REGN) reported on Wednesday first quarter earnings that beat analysts’ forecasts and revenue that topped expectations.
Regeneron Pharma announced earnings per share of $11.49 on revenue of $2.97B. Analysts polled by Investing.com anticipated EPS of $9.72 on revenue of $2.69B.
Regeneron Pharma shares are down 33.79% from the beginning of the year, still down 11.63% from its 52 week high of $747.42 set on April 8. They are under-performing the Nasdaq which is down 19.69% from the start of the year.
Regeneron Pharma follows other major Healthcare sector earnings this month
Regeneron Pharma’s report follows an earnings beat by J&J on April 19, who reported EPS of $2.67 on revenue of $23.43B, compared to forecasts EPS of $2.59 on revenue of $23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of $5.49 on revenue of $80.15B, compared to forecast for EPS of $5.36 on revenue of $78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar
